Prioritizing precision medicine for prostate cancer

Ann Oncol. 2015 Jun;26(6):1041-1042. doi: 10.1093/annonc/mdv179. Epub 2015 Apr 10.

Authors

G Attard¹, H Beltran²

Affiliations

¹ The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. Electronic address: gerhardt.attard@icr.ac.uk.
² Division of Medicine, Weill Cornell Medical College, New York, USA.

PMID: 25862438
DOI: 10.1093/annonc/mdv179

No abstract available

Publication types

Editorial
Comment

MeSH terms

Biomarkers, Tumor / genetics*
Gene Expression Profiling / methods*
Humans
Male
Prostatic Neoplasms / genetics*

Substances

Biomarkers, Tumor

Grants and funding